YS Biopharma Co Ltd
NASDAQ:LSB

Watchlist Manager
YS Biopharma Co Ltd Logo
YS Biopharma Co Ltd
NASDAQ:LSB
Watchlist
Price: 3.65 USD 8.96%
Market Cap: 69.6m USD
Have any thoughts about
YS Biopharma Co Ltd?
Write Note

Wall Street
Price Targets

LSB Price Targets Summary
YS Biopharma Co Ltd

Wall Street analysts forecast LSB stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LSB is 3.16 USD with a low forecast of 3.13 USD and a high forecast of 3.26 USD.

Lowest
Price Target
3.13 USD
14% Downside
Average
Price Target
3.16 USD
13% Downside
Highest
Price Target
3.26 USD
11% Downside
YS Biopharma Co Ltd Competitors:
Price Targets
RPTX
Repare Therapeutics Inc
316% Upside
206650
EuBiologics Co Ltd
17% Upside
1952
Everest Medicines Ltd
4% Upside
PSTX
Poseida Therapeutics Inc
476% Upside
084650
Labgenomics Co Ltd
40% Upside
APLT
Applied Therapeutics Inc
48% Upside
300142
Walvax Biotechnology Co Ltd
31% Upside
ALNY
Alnylam Pharmaceuticals Inc
1% Downside

Revenue
Forecast

Revenue Estimate
YS Biopharma Co Ltd

For the last 1 year the compound annual growth rate for YS Biopharma Co Ltd's revenue is -17%. The projected CAGR for the next 3 years is -24%.

-17%
Past Growth
-24%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
YS Biopharma Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
YS Biopharma Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LSB's stock price target?
Price Target
3.16 USD

According to Wall Street analysts, the average 1-year price target for LSB is 3.16 USD with a low forecast of 3.13 USD and a high forecast of 3.26 USD.

What is YS Biopharma Co Ltd's Revenue forecast?
Projected CAGR
-24%

For the last 1 year the compound annual growth rate for YS Biopharma Co Ltd's revenue is -17%. The projected CAGR for the next 3 years is -24%.

Back to Top